Target Name: RBM28
NCBI ID: G55131
Review Report on RBM28 Target / Biomarker Content of Review Report on RBM28 Target / Biomarker
RBM28
Other Name(s): RNA-binding motif protein 28 | RNA binding motif protein 28, transcript variant 1 | FLJ10377 | RBM28 variant 1 | RNA-binding protein 28 | ANES | RNA-binding protein 28 (isoform 1) | 2810480G15Rik | RBP28 | RNA binding motif protein 28 | RBM28_HUMAN

RBM28: A RNA-Binding Motif Protein with Potential Drug Targets

RNA-binding motif protein 28 (RBM28) is a protein that plays a critical role in various cellular processes. It is a member of the RBM28 family, which is known for its ability to interact with RNA molecules. RBM28 is highly expressed in various tissues and organs, including brain, heart, liver, and pancreas. It is involved in a wide range of cellular processes, including cell signaling, DNA replication, and repair, and has been implicated in many diseases, including cancer.

One of the key functions of RBM28 is its ability to interact with RNA molecules. This interaction is crucial for the regulation of various cellular processes, including cell signaling, DNA replication, and repair. RBM28 has been shown to interact with numerous RNA molecules, including microRNA (miRNA), long non-coding RNA (lncRNA), and RNA viruses.

In addition to its role in interacting with RNA molecules, RBM28 is also involved in the regulation of protein synthesis and degradation. It has been shown to play a role in the regulation of protein synthesis by interacting with the translation factors eIF4F and IF3. It is also involved in the regulation of protein degradation by interacting with the protein degradation machinery, including the 26S proteasome.

The RBM28 protein is highly expressed in various tissues and organs, including the brain, heart, liver, and pancreas. It is a key player in many cellular processes, including cell signaling, DNA replication, and repair. It is also involved in the regulation of protein synthesis and degradation.

Despite its involvement in many important cellular processes, the function of RBM28 is not well understood. Research into RBM28 is still in its infancy, and much more research is needed to fully understand its role in cellular processes.

One potential drug target for RBM28 is the inhibition of its activity. This could be done using small molecules, antibodies, or other therapeutic approaches. The use of small molecules, such as inhibitors of protein-protein interactions, is a common approach for the inhibition of protein functions. Antibodies, such as monoclonal antibodies, can also be used to target RBM28 and inhibit its activity.

Another potential approach to targeting RBM28 is the use of RNA-based therapeutics. RNA-based therapeutics are a type of therapeutic that use small interfering RNA (siRNA) or RNA interference (RNAi) to treat diseases. RBM28 is a good candidate for RNA-based therapeutics due to its high expression and involvement in cellular processes.

In conclusion, RBM28 is a protein that plays a critical role in various cellular processes. It is involved in cell signaling, DNA replication, and repair, and has been implicated in many diseases, including cancer. The inhibition of its activity is a potential drug target, and RNA-based therapeutics may also be used to target RBM28. Further research is needed to fully understand its role in cellular processes and develop effective treatments.

Protein Name: RNA Binding Motif Protein 28

Functions: Nucleolar component of the spliceosomal ribonucleoprotein complexes

The "RBM28 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RBM28 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

RBM3 | RBM33 | RBM34 | RBM38 | RBM39 | RBM4 | RBM41 | RBM42 | RBM43 | RBM43P1 | RBM44 | RBM45 | RBM46 | RBM47 | RBM48 | RBM48P1 | RBM4B | RBM5 | RBM5-AS1 | RBM6 | RBM7 | RBM8A | RBMS1 | RBMS1P1 | RBMS2 | RBMS2P1 | RBMS3 | RBMS3-AS3 | RBMX | RBMX2 | RBMX2P1 | RBMXL1 | RBMXL2 | RBMXL3 | RBMY1A1 | RBMY1B | RBMY1D | RBMY1F | RBMY1J | RBMY2EP | RBMY2FP | RBP1 | RBP2 | RBP3 | RBP4 | RBP5 | RBP7 | RBPJ | RBPJL | RBPJP2 | RBPMS | RBPMS-AS1 | RBPMS2 | RBSN | RBX1 | RC3H1 | RC3H2 | RCAN1 | RCAN2 | RCAN3 | RCAN3AS | RCBTB1 | RCBTB2 | RCC1 | RCC1L | RCC2 | RCCD1 | RCE1 | RCHY1 | RCL1 | RCN1 | RCN1P2 | RCN2 | RCN3 | RCOR1 | RCOR2 | RCOR3 | RCSD1 | RCVRN | RD3 | RD3L | RDH10 | RDH11 | RDH12 | RDH13 | RDH14 | RDH16 | RDH5 | RDH8 | RDM1 | RDUR | RDX | RDXP2 | Reactive oxygen species (ROS) | REC114 | REC8 | RECK | RECQL | RECQL4 | RECQL5